Objectives: Although statin has been known to be beneficial for secondary prevention of atherosclerotic cardiovascular disease (ASCVD), the favorable effects of statin in dialysis patients are controversial. Furthermore, there is limited evidence regarding trends of statin use and outcomes in dialysis patients with ASCVD. Methods: Patients undergoing chronic dialysis aged ≥ 18 years who had a first ASCVD event from 2013 to 2018 were included from the Korean National Health Insurance Service data. Annual trends of statin prescribing patterns and 1-year mortality based on statin intensity and each specific ASCVD diagnoses were evaluated.  Results: Among a total of 17,242 subjects, 9,611 (55.7%) patients were statin users. The overall prevalence of statin use increased from 52.9% in 2013 to 57.7% in 2018. Statin prescriptions significantly increased in dialysis patients under 65 years but were similar in males and females. The proportions of low- or moderate-intensity statin use were similar, but high-intensity statin use rose from 5.7% in 2013 to 10.5% in 2018. Atorvastatin was the most widely prescribed statin, and the use of statin/ezetimibe combination was gradually increased since 2016. Statin users remained at lower risk for 1-year all-cause mortality than statin non-users after adjusting confounding factors (Hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.80-0.96, P = 0.004). Low- or moderate-intensity statin use were independently associated with the reduced 1-year all-cause mortality (Low: HR 0.56, 95% CI 0.32-0.99, P = 0.046, Moderate: HR 0.89, 95% CI 0.80-0.97, P = 0.013). Moderate-intensity statin significantly decreased 1-year mortality in patients with coronary heart disease, and moderate- or high-intensity statin significantly decreased 1-year mortality in patients with cerebrovascular disease. Conclusions: The prevalence of statin prescription for secondary prevention substantially increased from 2013 to 2018. The statin use might be beneficial for decreasing short-term overall mortality in dialysis patients with ASCVD.